

REMARKS

By this amendment, claims 2, 4-6, 13-32 and 37-56 are canceled. Claims 1, 3, 7-9, 11, 12, 33-36 and 57-60 are allowed. Claims 1, 3, 7-12, 33-36 and 57-60 are pending. Claim 10 has been amended.

In view of the amendment and associated Remarks, reconsideration and withdrawal of all outstanding rejections are deemed proper.

Rejection under 35 USC §101

Claims 37 and 38 were rejected under 35 U.S.C. §101 as allegedly encompassing¹ a human being. Claims 37 and 38 have been canceled. Reconsideration and withdrawal of this rejection are respectfully requested.

Rejection under 35 USC §112, second paragraph

Claim 10 is rejected under 35 U.S.C. §112, second paragraph as allegedly being indefinite. Claim 10 has been amended to delete "at position -1". Reconsideration and withdrawal of this rejection are respectfully requested.

Rejections under 35 USC §102

Claims 2, 5, 6, 13, and 14 stand rejected over Langmann. Claims 2, 5, 6, 13 and 14 are canceled. Reconsideration and withdrawal of this rejection are respectfully requested.


Conclusion

In view of the above amendments and remarks, Applicants respectfully request reconsideration and withdrawal of all pending rejections. Applicants respectfully submit that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance.

Fees

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

Respectfully submitted,



Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626

Docket No. ST00015 US NP